SonoCloud

Low Intensity Contact Ultrasound Implant 

The SonoCloud® Device

The SonoCloud® is an implantable medical device, which is fixed to the skull. Since the device must be MRI compatible, the device does not contain any integrated power source. The upper face, which is in contact with the underside of the skin, contains a connection channel that receives a bipolar needle which is introduced through the skin at each use. The bottom face, which is in contact with the dura mater and brain, consists of a transducer that emits ultrasound energy to open the blood-brain barrier.

The SonoCloud® device is powered and controlled by an external generator that verifies the quality of the electrical connection, delivers radio-frequency energy to power the device, and saves the entire procedure sequence.

Illustration of the top face of the SonoCloud®, which accepts a power source temporarily through a transcutaneous needle connection. The connection can be easily made by a nurse during each BBB opening procedure.

SonoCloud111

  • unnamed-2
    unnamed-3

     
  • News CarThera

    18.05.2018
    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.

    03.07.2017
    CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) on ultrasound induced Blood-Brain Barrier opening revealed preliminary safety and efficacy data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.

    14.10.2016
    CarThera secures €5.7 million in funding for its DOME project

    October 12, 2016 – CarThera has received a grant of €5.7 million ($6.4m) for its DOME project. The funding was awarded under the call for proposals ‘Structuring R&D Projects for Competitiveness’ from France’s ‘Investments for the Future Program’, led by the General Investment Commission and run by Bpifrance.

    The grant will finance our SonoCloud Phase 2b/3 study in glioblastoma that will involve around 200 patients at centers in Europe and the United States. It will also fund a number of exploratory studies, including one on Alzheimer’s disease, building on the findings from the Phase 1/2a study that paved the way for a broader array of clinical indications.